TGFB1 and systemic sclerosis: Assessment of microangiopathy in NFC of SSc animal models or RP models could enable research of leukotriene pathways, their interactions with other mediators (i.e., TGF-β, Hypoxia inducible factor 1α, among others), and the usefulness of antileukotriene therapy and other pathogenic mediators or potential antifibrotic therapies in SSc.